CO7101191A2 - Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo - Google Patents
Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismoInfo
- Publication number
- CO7101191A2 CO7101191A2 CO14146333A CO14146333A CO7101191A2 CO 7101191 A2 CO7101191 A2 CO 7101191A2 CO 14146333 A CO14146333 A CO 14146333A CO 14146333 A CO14146333 A CO 14146333A CO 7101191 A2 CO7101191 A2 CO 7101191A2
- Authority
- CO
- Colombia
- Prior art keywords
- novel
- preparation
- platform system
- anthobiotic
- system based
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 3
- 238000009509 drug development Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Se proporcionan un método de preparación de antibiótico novedoso y sistema de plataforma en función del método, que pertenece a un método de desarrollo de fármaco novedoso. El método se basa en una fórmula estructural fija: F-R, en donde F es un área de efecto, y R es un área de identificación. En el nivel anterior, la presente invención puede desarrollar rápidamente un antibiótico novedoso específico para la mayoría de microorganismos patogénicos o células biológicas, También se proporciona una plataforma para implementar el método, asegurando que se desarrolla el antibiótico novedoso en un proceso simplificado eficiente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110405775 | 2011-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7101191A2 true CO7101191A2 (es) | 2014-10-31 |
Family
ID=48573572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14146333A CO7101191A2 (es) | 2011-12-08 | 2014-07-08 | Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo |
Country Status (21)
Country | Link |
---|---|
US (1) | US10071358B2 (es) |
EP (1) | EP2789632B1 (es) |
JP (2) | JP2015507471A (es) |
KR (2) | KR20140104475A (es) |
CN (1) | CN103159856B (es) |
AP (1) | AP2014007769A0 (es) |
AU (1) | AU2012349080B2 (es) |
BR (1) | BR112014013735A2 (es) |
CA (1) | CA2857976A1 (es) |
CO (1) | CO7101191A2 (es) |
DK (1) | DK2789632T3 (es) |
EA (1) | EA201400634A1 (es) |
ES (1) | ES2686341T3 (es) |
HK (1) | HK1197247A1 (es) |
IL (1) | IL232995B (es) |
IN (1) | IN2014KN01420A (es) |
PH (1) | PH12014501276A1 (es) |
SG (1) | SG11201402990YA (es) |
TW (1) | TWI557225B (es) |
WO (1) | WO2013083095A1 (es) |
ZA (1) | ZA201404527B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
CN102747041B (zh) | 2011-04-21 | 2014-07-16 | 畿晋庆三联(北京)生物技术有限公司 | 抗蓝藻重组抗体多肽及其基因与制备方法 |
CN108341869A (zh) * | 2016-12-26 | 2018-07-31 | 畿晋庆三联(北京)生物技术有限公司 | 抗结核分枝杆菌(Mycobacterium tuberculosis)及其感染的药物及其应用 |
US11125750B2 (en) * | 2018-06-28 | 2021-09-21 | The University Of Toledo | Methods, assays and kits for detecting exposure to cyanotoxins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1274829C (zh) | 2004-12-10 | 2006-09-13 | 四川大学华西医院 | 抗eb病毒所致肿瘤多肽及其应用与制备方法 |
DE102007036128A1 (de) * | 2007-07-23 | 2009-02-12 | Universität Leipzig | Antibiotische Peptide |
CN101200727B (zh) | 2007-12-21 | 2013-06-26 | 畿晋庆堂国际生物技术有限公司 | 抗农作物真菌多肽及其制备方法 |
CN101215568B (zh) * | 2008-01-18 | 2010-06-23 | 畿晋庆三联(北京)生物技术有限公司 | 抗炭疽多肽及其应用与制备方法 |
CN101643501B (zh) * | 2008-11-07 | 2012-06-20 | 畿晋庆三联(北京)生物技术有限公司 | 一种新型抗生素及其核苷酸序列、制备方法与应用 |
CN101633699B (zh) * | 2009-09-02 | 2012-02-15 | 畿晋庆堂国际生物技术有限公司 | 一种含抗体模拟物的新型抗生素及其制备方法与应用 |
CN102101888B (zh) * | 2009-12-17 | 2013-03-20 | 畿晋庆三联(北京)生物技术有限公司 | 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法 |
CN102747041B (zh) | 2011-04-21 | 2014-07-16 | 畿晋庆三联(北京)生物技术有限公司 | 抗蓝藻重组抗体多肽及其基因与制备方法 |
-
2012
- 2012-12-10 CN CN201210530282.7A patent/CN103159856B/zh active Active
- 2012-12-10 EA EA201400634A patent/EA201400634A1/ru unknown
- 2012-12-10 BR BR112014013735A patent/BR112014013735A2/pt unknown
- 2012-12-10 WO PCT/CN2012/086296 patent/WO2013083095A1/zh active Application Filing
- 2012-12-10 US US14/363,773 patent/US10071358B2/en active Active
- 2012-12-10 CA CA2857976A patent/CA2857976A1/en not_active Abandoned
- 2012-12-10 KR KR1020147018835A patent/KR20140104475A/ko active Application Filing
- 2012-12-10 ES ES12854873.2T patent/ES2686341T3/es active Active
- 2012-12-10 TW TW101146323A patent/TWI557225B/zh not_active IP Right Cessation
- 2012-12-10 JP JP2014545088A patent/JP2015507471A/ja active Pending
- 2012-12-10 SG SG11201402990YA patent/SG11201402990YA/en unknown
- 2012-12-10 AU AU2012349080A patent/AU2012349080B2/en not_active Ceased
- 2012-12-10 EP EP12854873.2A patent/EP2789632B1/en active Active
- 2012-12-10 AP AP2014007769A patent/AP2014007769A0/xx unknown
- 2012-12-10 KR KR1020167030859A patent/KR101916205B1/ko active IP Right Grant
- 2012-12-10 DK DK12854873.2T patent/DK2789632T3/en active
-
2014
- 2014-06-05 IL IL232995A patent/IL232995B/en active IP Right Grant
- 2014-06-06 PH PH12014501276A patent/PH12014501276A1/en unknown
- 2014-06-20 ZA ZA2014/04527A patent/ZA201404527B/en unknown
- 2014-07-04 IN IN1420KON2014 patent/IN2014KN01420A/en unknown
- 2014-07-08 CO CO14146333A patent/CO7101191A2/es unknown
- 2014-10-27 HK HK14110729A patent/HK1197247A1/xx not_active IP Right Cessation
-
2016
- 2016-09-20 JP JP2016183090A patent/JP6412077B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6412077B2 (ja) | 2018-10-24 |
TWI557225B (zh) | 2016-11-11 |
ZA201404527B (en) | 2017-04-26 |
EP2789632B1 (en) | 2018-06-06 |
AU2012349080B2 (en) | 2016-06-02 |
CN103159856B (zh) | 2015-02-25 |
NZ627116A (en) | 2016-07-29 |
JP2017023150A (ja) | 2017-02-02 |
PH12014501276A1 (en) | 2014-09-08 |
US10071358B2 (en) | 2018-09-11 |
EA201400634A1 (ru) | 2014-12-30 |
KR20140104475A (ko) | 2014-08-28 |
IN2014KN01420A (es) | 2015-10-23 |
CA2857976A1 (en) | 2013-06-13 |
EP2789632A4 (en) | 2015-07-22 |
HK1197247A1 (en) | 2015-01-09 |
CN103159856A (zh) | 2013-06-19 |
BR112014013735A2 (pt) | 2017-06-13 |
IL232995A0 (en) | 2014-07-31 |
JP2015507471A (ja) | 2015-03-12 |
WO2013083095A1 (zh) | 2013-06-13 |
KR101916205B1 (ko) | 2018-11-08 |
US20140349880A1 (en) | 2014-11-27 |
AP2014007769A0 (en) | 2014-07-31 |
AU2012349080A1 (en) | 2014-07-24 |
ES2686341T3 (es) | 2018-10-17 |
EP2789632A1 (en) | 2014-10-15 |
KR20160130531A (ko) | 2016-11-11 |
DK2789632T3 (en) | 2018-08-06 |
SG11201402990YA (en) | 2014-09-26 |
IL232995B (en) | 2018-01-31 |
TW201331363A (zh) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002805A1 (es) | Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) | |
DOP2013000030A (es) | Compuesto heterociclico y su uso | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
SV2015004979A (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contiene un grupo sulfoximina | |
ECSP15001882A (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
AR091776A1 (es) | Herramienta de deformacion desintegrable | |
CO6440530A2 (es) | Formulaciones de caldo de fermentación | |
GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
GT201400162A (es) | Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas | |
ES2488407T3 (es) | Preparación farmacéutica que contiene lipasa de origen bacteriano | |
UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
BR112015006524A2 (pt) | derivados de quinazolinona como inibidores de parp | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
CO6751260A2 (es) | Vacunas basadas en omv contra infecciones por burkholderia | |
CO7101191A2 (es) | Método de preparación de antobiótico novedoso y sistema de plataforma con base en el mismo | |
CR20150257A (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina | |
DOP2014000114A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
UY35439A (es) | Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo. | |
BR112013033759A8 (pt) | Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol | |
BR112015030431A2 (pt) | formulação de liberação modificada | |
ECSP17068868A (es) | Archaebacteria en alimento para animales bioactivo, método para hacer la composición y métodos que emplean la composición | |
BR112016010159A2 (pt) | usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit |